The compound you've described, **1-[2-[cyano-(4,6-dimethyl-2-pyrimidinyl)amino]-1-oxoethyl]-4-piperidinecarboxamide**, is actually a very important drug with the brand name **Sorafenib**.
Here's why it's important:
* **Cancer Treatment:** Sorafenib is a **multi-kinase inhibitor**, meaning it blocks the activity of multiple kinases, which are enzymes that play a crucial role in cell signaling and growth. It targets specific kinases involved in the growth and spread of cancer cells, including:
* **VEGFR:** Vascular endothelial growth factor receptor, which is important for the formation of new blood vessels that tumors need to grow.
* **RAF:** A kinase involved in the RAS/RAF/MEK/ERK signaling pathway, a key pathway in tumor development and proliferation.
* **c-KIT:** A receptor tyrosine kinase involved in the growth and survival of certain types of cancer cells.
* **Clinical Applications:** Sorafenib is approved by the FDA for the treatment of:
* **Advanced renal cell carcinoma (RCC):** A type of kidney cancer.
* **Advanced hepatocellular carcinoma (HCC):** A type of liver cancer.
* **Advanced thyroid cancer:** A type of cancer in the thyroid gland.
* **Unresectable, locally advanced or metastatic differentiated thyroid cancer:** In this case, Sorafenib is used in combination with other therapies.
* **Mechanism of Action:** Sorafenib inhibits the activity of these kinases, preventing cancer cells from receiving the signals they need to grow and spread. This leads to the suppression of tumor growth and potentially even regression.
* **Ongoing Research:** Sorafenib is still under investigation for its potential use in treating other types of cancer, as well as for other medical conditions. Researchers are exploring its effectiveness in combination with other therapies and are looking for ways to improve its delivery and efficacy.
Overall, Sorafenib is a vital medication for patients with certain types of cancer, offering significant hope for improved survival and quality of life. Its mechanism of action and clinical applications highlight the importance of kinase inhibitors in cancer treatment and the ongoing research efforts to refine and expand their use.
| ID Source | ID |
|---|---|
| PubMed CID | 666064 |
| CHEMBL ID | 1299689 |
| CHEBI ID | 120690 |
| Synonym |
|---|
| HMS1697F16 |
| smr000047416 |
| MLS000083540 |
| 1-[n-cyano-n-(4,6-dimethylpyrimidin-2-yl)glycyl]piperidine-4-carboxamide |
| STK202845 |
| CHEBI:120690 |
| MLS002584383 |
| 1-[2-[cyano-(4,6-dimethylpyrimidin-2-yl)amino]acetyl]piperidine-4-carboxamide |
| AKOS000629221 |
| CHEMBL1299689 |
| HMS2376O10 |
| 1-[2-[cyano-(4,6-dimethyl-2-pyrimidinyl)amino]-1-oxoethyl]-4-piperidinecarboxamide |
| Q27208824 |
| BRD-K01182779-001-09-0 |
| Class | Description |
|---|---|
| organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
| organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 10.0000 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 7.9433 | 0.0072 | 15.7588 | 89.3584 | AID411 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.1995 | 0.0013 | 18.0743 | 39.8107 | AID926 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 100.0000 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 1.9931 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 3.9811 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 3.9811 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||